Israeli drugmaker Teva Pharmaceutical Industries Ltd. said Wednesday it received tentative Food and Drug Administration approval for a generic version of GlaxoSmithKline PLC's Imitrex migraine treatment.

The tentative approval covers 25-milligram, 50-milligram and 100-milligram strength tablets of sumatriptan succinate, the active ingredient in Imitrex.

Teva expects final approval when the patent for Imitrex expires in February 2009.

The branded product accounted for about $910 million in sales for the 12 months ending in September, according to industry data.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP